Joseph Priestley Society: Rachel K. King

Joseph Priestley Society
Thursday, March 16, 2017
11:30 a.m.–2:00 p.m.
Chemical Heritage Foundation
315 Chestnut Street
Philadelphia, PA 19106
United States

the Institute is pleased to welcome Rachel K. King, CEO, GlycoMimetics. King will deliver a keynote address entitled “Reflections on Building a Biotech Company: The Story (So Far!) of GlycoMimetics.”

King will tell the story of GlycoMimetics (GMI) from its founding, through the company’s initial public offering, to the present day. GMI has three drug candidates currently in clinical testing: rivipansel, being tested in sickle-cell disease; GMI-1271, being tested in acute myelogenous leukemia and multiple myeloma; and GMI-1359, which is being considered for testing in a range of cancers. She will discuss the ups, the downs, and the challenges of building a company in this industry and will share reflections on the importance of the work done in biotechnology.


Event Schedule

  • 11:30 a.m.
    Networking Reception
  • 12:15 p.m.
  • 1:00 p.m. 
    Keynote Address

The Joseph Priestley Society (JPS) lecture series explores topics in science, technology, and industry through professional networking receptions and lectures by industry leaders.

For more information about this event, please contact Sarah Reisert at 215.873.8263 or

About the Speaker

Rachel King

Rachel King

Rachel King

Rachel King is cofounder and CEO of GlycoMimetics, Inc. (GMI), a biotechnology company that raised over $60 million in venture capital financing, entered into a major strategic partnership with Pfizer, and went public in early 2014. Before founding GMI she was an executive in residence at New Enterprise Associates, one of the nation’s leading venture capital firms. King came to New Enterprise Associates after serving as a senior vice president of Novartis Corporation. Before joining Novartis, she spent 10 years with Genetic Therapy, Inc., through the company’s early stage, initial public offering, and eventual sale to Novartis. After the sale she was named CEO and ran the company as a wholly owned subsidiary of Novartis. King also worked previously at ALZA Corporation in Palo Alto, California, and at Bain and Company in Boston.

She is the immediate past chair of the board of the Biotechnology Innovation Association (BIO) and continues to serve on BIO’s Executive Committee. She also served as chair of the Maryland Life Sciences Advisory Board under Governor Martin O’Malley and now serves on the board of directors of Warp Drive Bio and of the University of Maryland BioPark. King received her BA degree from Dartmouth College and her MBA from the Harvard Business School.